Cycle, cravings, and sleep are one story

If you have a PCOS diagnosis, what you have is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. What this article describes (how sleep, cortisol, insulin, and androgens feed each other in PMOS) is unchanged by the rename.

You sleep badly. The next day you crave sugar. The day after that your energy crashes. A week later your period is late. You tell a clinician about four problems. The clinician treats four problems. Nothing meaningfully improves.

This is a familiar frustration in living with PMOS. The features look like separate events; they are one system in a loop, and treating them as separate is part of why a series of interventions can each be reasonable on its own and still produce no durable change. This article explains the loop: how sleep, cortisol, insulin, and androgens talk to each other in PMOS, and where intervening can quiet the whole system.

The four players

Before connecting them, a brief introduction. Each of these is a normal body function; they become a problem when they get stuck in a reinforcing loop, which is what happens in PMOS.

Sleep. Specifically slow-wave (deep) sleep, the restorative stage in which the body recalibrates hormone signals, repairs tissue, and resets insulin sensitivity. PMOS is associated with both reduced deep sleep and elevated rates of obstructive sleep apnoea, including in people at a lean body weight.

Cortisol. The primary stress hormone. It is meant to peak in the morning and drop at night. Under chronic stress, including the metabolic stress of fragmented sleep, cortisol stays elevated, particularly at night when it should be quiet.

Insulin. The hormone that tells cells to absorb glucose. When cells respond less efficiently (insulin resistance), the pancreas releases more to compensate. The 2026 Lancet rename consensus reports approximately 85 percent of people with PMOS overall, and approximately 75 percent at a lean body weight, have insulin resistance.

Androgens. Testosterone, DHEA-S, and their active metabolites. Everyone produces them; in PMOS, levels and biological activity tend to be elevated. They are the upstream driver of acne, hair changes, and contributions to ovulation disruption. The mechanism page on why PMOS raises androgens covers this in depth.

The loop, in order

A typical sequence of cause and effect in the PMOS loop:

1. Sleep is disrupted or short. Often through stress, often through low-grade sleep-disordered breathing, often through the metabolic stress of the condition itself.
2. Cortisol rises and stays up. Next-day morning cortisol is elevated; evening cortisol fails to drop.
3. Insulin resistance worsens. Elevated cortisol contributes to less efficient glucose uptake in cells; the pancreas compensates with more insulin.
4. Androgens rise. Elevated insulin drives ovarian theca-cell androgen production and suppresses SHBG, increasing free testosterone. The adrenal source contributes in parallel for the 20 to 30 percent of people with PMOS who have elevated DHEA-S.
5. Sleep suffers more. Elevated androgens are associated with poorer sleep quality, more fragmented deep sleep, and higher rates of sleep-disordered breathing. The loop closes.

Each cycle tightens the next. The features feel like separate problems because they appear at different points in the day or month, but they are connected upstream.

How sleep starts the loop

A short or fragmented night of sleep raises the next day’s cortisol, sometimes substantially, depending on severity and duration. This is not a subjective "I’m tired" feeling; it is a measurable neuroendocrine shift that the body registers as a threat signal.

Cortisol’s role in that moment is to mobilise energy. It signals the liver to release glucose and tells cells to be less responsive to insulin, because the body, reading stress, wants glucose available in the bloodstream rather than locked away in cells. Helpful in an acute emergency. Problematic when it is happening multiple nights a week, every week, for years.

How insulin drives androgens

This is the link many people with PMOS never get explained to them. Ovarian theca cells carry insulin receptors. When insulin levels are persistently elevated (because cells are responding less efficiently and the pancreas is compensating), that excess insulin reaches the ovaries and stimulates them to increase androgen production. Insulin also suppresses SHBG production in the liver. SHBG is the protein that normally binds testosterone and keeps it inactive; less SHBG means more free testosterone circulating.

This is why the PMOS features that feel most distressing (acne, facial and body hair, scalp hair thinning, missed or late periods) are often downstream of a mechanism that has very little to do with skin or hair, and very much to do with how insulin and androgens are signalling over time. The insulin resistance pillar covers this in greater detail.

How androgens disrupt sleep

Elevated androgens, particularly in the evening, are associated with poorer sleep quality, more fragmented deep sleep, and higher rates of sleep-disordered breathing in PMOS populations. The full mechanism is still being studied; the association is consistent enough that endocrinology and sleep-medicine literature treat sleep as a core feature of PMOS care rather than a lifestyle sidenote.

The loop closes: androgens up, sleep suffers, cortisol up the next day, insulin resistance worsens, androgens rise further.

Why this changes how PMOS gets treated

If a series of single-symptom interventions has felt like it does not produce lasting change, the loop is part of why. The treatment implication is actually clarifying: there is no need to fix every link at once. Intervening at any point can quiet the whole system, because each step depends on the previous one to keep going.

Better sleep lowers next-day cortisol, which reduces insulin resistance, which lowers the upstream driver for ovarian androgen production. This is why the 2023 International Guideline names sleep as a core foundation intervention, not an add-on.

Engaging insulin resistance directly (lifestyle foundation interventions, metformin where indicated, inositol as adjunct, GLP-1 receptor agonists where indicated) reduces ovarian theca-cell androgen production and improves SHBG. The PMOS treatment hierarchy covers the full ordering.

Addressing androgens at the receptor level (anti-androgens like spironolactone, where appropriate) can secondarily improve sleep, particularly when the androgen-to-sleep pathway is contributing significantly.

Reducing chronic stress load (sleep regularity, movement, social and emotional resources) engages the cortisol arm of the loop without requiring a clinical intervention.

These are not "just eat clean" or "balance your hormones" framings. They are specific interventions that engage specific links in a specific loop. The 2023 International Guideline supports each of them.

What to ask a clinician

If the PMOS features described in this article are clustering and a workup has not addressed the loop, the practical asks for the next appointment:

Has my fasting insulin been tested, not just my fasting glucose? Insulin resistance can be present while glucose is in range.

What are my SHBG and free testosterone, not just my total testosterone?

Has DHEA-S been checked for an adrenal androgen contribution?

Has sleep been part of the conversation, including obstructive sleep apnoea screening if symptoms are present?

These four lines of inquiry tell a connected story. Most routine panels miss the insulin, SHBG, and sleep questions.